SU14813

• CAT Number: I004366
• CAS Number: 627908-92-3
• Molecular Formula: C23H27FN4O4
• Molecular Weight: 442.48
• Purity: ≥95%
• Synonyms: (Z)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-N-(2-hydroxy-3-morpholinopropyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide
• Target: PTKs/RTKs
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C

SU14813 is an oral, multitargeted tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), Kit, and fms-like tyrosine kinase 3 (FLT-3).IC50 value:Target: VEGFR/PDGFR/Flt-3/kitSU14813 was developed as a next-generation TKI agent following sunitinib (SU11248) designed to demonstrate optimized pharmacokinetic (PK) and tolerability profiles. SU14813 demonstrated broad and potent antitumor activity equivalent to that of sunitinib, which resulted in tumor regression, growth arrest, growth delay, and prolonged survival in established xenograft cancer models in mice.

Reference

[1]. Patyna S, et al. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther. 2006 Jul;5(7):1774-82.
[2]. Hu-Lowe D, et al. The discovery and development of SU14813, a next-generation multitargeted tyrosine kinase inhibitor for the treatment of human malignancies. Mol Cancer Ther. 2011 Nov;10(11):2015.